Mining the adenovirus virome for oncolytics against multiple solid tumor types

C. Y. Chen, E. A. Weaver, R. Khare, S. M. May, Michael A Barry

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Although there are 55 serotypes of adenovirus (Ad) that infect humans, Ad serotype 5 (Ad5) is the most widely studied because of the availability of commercial kits for its genetic manipulation. In fact, engineered Ad 5 is currently being used in all of the 87 global clinical trials utilizing Ad for the treatment of cancer. Unfortunately, Ad5 is one of the most seroprevalent serotypes, meaning that this virus has to confront additional immunological barriers to be effective in Ad5-immune patients. In this work, we compare Ad5 to 13 other adenoviral serotypes from species B, C, D and E for oncolytic potential in both immunodeficient mouse and immunocompetent hamster models. Our results indicate that species D Ads are not effective oncolytics against most solid tumors. Conversely, lower seroprevalent Ad6 and Ad11 had anti-cancer activity comparable to Ad5. This work strongly supports the consideration of Ad6-based oncolytic therapies for the treatment of breast, ovarian, kidney and liver tumors.

Original languageEnglish (US)
Pages (from-to)744-750
Number of pages7
JournalCancer Gene Therapy
Volume18
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

Adenoviridae
Neoplasms
Human Adenoviruses
Serogroup
Cricetinae
Breast
Therapeutics
Clinical Trials
Viruses
Kidney
Liver

Keywords

  • adenovirus
  • cancer
  • oncolytic

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Mining the adenovirus virome for oncolytics against multiple solid tumor types. / Chen, C. Y.; Weaver, E. A.; Khare, R.; May, S. M.; Barry, Michael A.

In: Cancer Gene Therapy, Vol. 18, No. 10, 10.2011, p. 744-750.

Research output: Contribution to journalArticle

Chen, C. Y. ; Weaver, E. A. ; Khare, R. ; May, S. M. ; Barry, Michael A. / Mining the adenovirus virome for oncolytics against multiple solid tumor types. In: Cancer Gene Therapy. 2011 ; Vol. 18, No. 10. pp. 744-750.
@article{dc4e51ae6b044f05abd0cdf570839d6d,
title = "Mining the adenovirus virome for oncolytics against multiple solid tumor types",
abstract = "Although there are 55 serotypes of adenovirus (Ad) that infect humans, Ad serotype 5 (Ad5) is the most widely studied because of the availability of commercial kits for its genetic manipulation. In fact, engineered Ad 5 is currently being used in all of the 87 global clinical trials utilizing Ad for the treatment of cancer. Unfortunately, Ad5 is one of the most seroprevalent serotypes, meaning that this virus has to confront additional immunological barriers to be effective in Ad5-immune patients. In this work, we compare Ad5 to 13 other adenoviral serotypes from species B, C, D and E for oncolytic potential in both immunodeficient mouse and immunocompetent hamster models. Our results indicate that species D Ads are not effective oncolytics against most solid tumors. Conversely, lower seroprevalent Ad6 and Ad11 had anti-cancer activity comparable to Ad5. This work strongly supports the consideration of Ad6-based oncolytic therapies for the treatment of breast, ovarian, kidney and liver tumors.",
keywords = "adenovirus, cancer, oncolytic",
author = "Chen, {C. Y.} and Weaver, {E. A.} and R. Khare and May, {S. M.} and Barry, {Michael A}",
year = "2011",
month = "10",
doi = "10.1038/cgt.2011.47",
language = "English (US)",
volume = "18",
pages = "744--750",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Mining the adenovirus virome for oncolytics against multiple solid tumor types

AU - Chen, C. Y.

AU - Weaver, E. A.

AU - Khare, R.

AU - May, S. M.

AU - Barry, Michael A

PY - 2011/10

Y1 - 2011/10

N2 - Although there are 55 serotypes of adenovirus (Ad) that infect humans, Ad serotype 5 (Ad5) is the most widely studied because of the availability of commercial kits for its genetic manipulation. In fact, engineered Ad 5 is currently being used in all of the 87 global clinical trials utilizing Ad for the treatment of cancer. Unfortunately, Ad5 is one of the most seroprevalent serotypes, meaning that this virus has to confront additional immunological barriers to be effective in Ad5-immune patients. In this work, we compare Ad5 to 13 other adenoviral serotypes from species B, C, D and E for oncolytic potential in both immunodeficient mouse and immunocompetent hamster models. Our results indicate that species D Ads are not effective oncolytics against most solid tumors. Conversely, lower seroprevalent Ad6 and Ad11 had anti-cancer activity comparable to Ad5. This work strongly supports the consideration of Ad6-based oncolytic therapies for the treatment of breast, ovarian, kidney and liver tumors.

AB - Although there are 55 serotypes of adenovirus (Ad) that infect humans, Ad serotype 5 (Ad5) is the most widely studied because of the availability of commercial kits for its genetic manipulation. In fact, engineered Ad 5 is currently being used in all of the 87 global clinical trials utilizing Ad for the treatment of cancer. Unfortunately, Ad5 is one of the most seroprevalent serotypes, meaning that this virus has to confront additional immunological barriers to be effective in Ad5-immune patients. In this work, we compare Ad5 to 13 other adenoviral serotypes from species B, C, D and E for oncolytic potential in both immunodeficient mouse and immunocompetent hamster models. Our results indicate that species D Ads are not effective oncolytics against most solid tumors. Conversely, lower seroprevalent Ad6 and Ad11 had anti-cancer activity comparable to Ad5. This work strongly supports the consideration of Ad6-based oncolytic therapies for the treatment of breast, ovarian, kidney and liver tumors.

KW - adenovirus

KW - cancer

KW - oncolytic

UR - http://www.scopus.com/inward/record.url?scp=80052966552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052966552&partnerID=8YFLogxK

U2 - 10.1038/cgt.2011.47

DO - 10.1038/cgt.2011.47

M3 - Article

VL - 18

SP - 744

EP - 750

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 10

ER -